Sacituzumab tirumotecan

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 04:46:48 GMT 2025` Edited by `admin` on `Wed Apr 02 04:46:48 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	3DV5TD1VL3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SKB-264

Preferred Name

English

Sacituzumab tirumotecan

Official Name

English

Sacituzumab tirumotecan [WHO-DD]

Common Name

English

SKB264

Code

English

sacituzumab tirumotecan [INN]

Common Name

English

MK-2870

Code

English

Immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epit

Common Name

English

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal hRS7 ?1-chain), disulfide with human-Mus musculus monoclonal hRS7 ?-chain, dimer, reduced, S-[5-[6-[[[1-[(34S)-38-amino-34-[[[4-[[[[[(4S)-4-ethyl-

Common Name

English

MK2870

Code

English

Code System Code Type Description

CAS

2768350-77-0

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

PRIMARY

NCI_THESAURUS

C166409

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

PRIMARY

WIKIPEDIA

MK-2870

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

SUPERSEDED

SMS_ID

300000047924

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

PRIMARY

FDA UNII

3DV5TD1VL3

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

PRIMARY

INN

12801

Created by admin on Wed Apr 02 04:46:48 GMT 2025 , Edited by admin on Wed Apr 02 04:46:48 GMT 2025

PRIMARY

From	To
1_22	1_96
1_148	1_204
1_224	3_214
1_230	2_230
1_233	2_233
1_265	1_325
1_371	1_429
2_22	2_96
2_148	2_204
2_224	4_214
2_265	2_325
2_371	2_429
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_301
N	2_301

Related Record Type Details


					73H2I6QS54

CONJUGATE COMPONENT->CONJUGATE

Amount:


					GM1W90Y88M

TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2

TARGET -> INHIBITOR

Amount:


					FUV56ZH0GB

DNA TOPOISOMERASE 1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					3DV5TD1VL3

Sacituzumab tirumotecan

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION		RESIDUE_SPECIFIC	C	Amount:	UNSPECIFIED SUBSTANCE	0a768de7 (not in database)
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS	Q		PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL